<div id="readability-page-1"><div><p>LivaNova (LIVN) opened Q1 2026 with revenue of US$362.3 million and basic EPS of US$0.41, while trailing twelve month revenue stood at US$1.4 billion and basic EPS at US$1.96. Together, these figures frame a year in which the company moved back into positive earnings territory. Over recent quarters, revenue has shifted from US$316.9 million in Q1 2025 to US$362.3 million in Q1 2026, with quarterly basic EPS moving from a loss of US$6.01 to a profit of US$0.41. This points to a cleaner earnings profile and tighter cost control that may be relevant for investors focused on margins.</p> <p>See our full analysis for LivaNova.</p><p>With the latest numbers on the table, the next step is to see how this earnings profile lines up with the dominant narratives around LivaNova and where those stories might need updating.</p> <p>See what the community is saying about LivaNova</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c4258a7-0182-4814-9995-c80a9d257cb7/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTA3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c4258a7-0182-4814-9995-c80a9d257cb7/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTA3"/><figcaption>NasdaqGS:LIVN Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>Five year profit growth meets cleaner recent margins</h2> <ul> <li>Trailing twelve month net income swung from a loss of US$242.5 million in the prior period to a profit of US$107.1 million, while five year earnings growth is cited at 29.8% a year.</li> <li>Consensus narrative expects clinical data, new therapies and higher recurring revenue to support earnings quality, yet the step from a US$380.8 million one off loss to four straight quarters of positive net income (US$22.3 million to US$55.9 million per quarter across the last six data points) asks you to judge how repeatable recent margins really are.     <ul> <li>Supporters point to consistent quarterly profits since Q2 2025, with net income excluding extra items between US$26.8 million and US$30.9 million before Q1 2026, as evidence that profitability is not just a one quarter event.</li> <li>On the other hand, the large one off loss still sits inside the last twelve month window, so trailing metrics mix together that past hit with the newer earnings profile, which can make trend lines look bumpier than the recent run rate.</li> </ul> </li> </ul> <h2>Revenue trend steady while bulls focus on higher growth</h2> <ul> <li>Total revenue has moved from US$316.9 million in Q1 2025 to US$362.3 million in Q1 2026, with trailing twelve month revenue at about US$1.4b compared with US$1.3b a year earlier, alongside a revenue growth forecast of 5.6% a year.</li> <li>Bullish investors argue that new therapies and reimbursement support could justify revenue growth of around 7% a year and higher long term margins, yet the current data set shows a more measured revenue path and emphasizes the importance of those future adoption and pricing assumptions.     <ul> <li>Consensus points to double digit procedure growth and international expansion as potential drivers, but the reported figures so far show quarterly revenue increasing in relatively small steps of roughly US$4 million to US$8 million at a time.</li> <li>This creates a clear cross check for the bullish view, as any gap between the forecast 7% style growth and the current 5.6% revenue growth forecast will hinge on how quickly new launches and reimbursement changes translate into actual sales.</li> </ul> </li> </ul><p> On these numbers, bulls are effectively betting that the gradual revenue climb you see today is just the early phase of a larger growth curve, so it helps to compare the current trend with the fuller bullish case. <strong>🐂 LivaNova Bull Case</strong></p><h2>Rich 33.8x P/E keeps bears focused on valuation risk</h2> <ul> <li>The trailing P/E of 33.8x sits above both the US Medical Equipment industry average of 23.6x and a reported peer average of 3.9x, even though the share price of US$66.26 is below the DCF fair value of about US$106 and below the analyst price target of US$79.82.</li> <li>Bears highlight that relying on forecast earnings and DCF fair value to justify this P/E leaves little room for setbacks, while the move from a large one off loss of US$380.8 million to positive trailing earnings still feeds through the reported multiples.     <ul> <li>The improvement from a trailing twelve month net loss of US$222.1 million to a profit of US$107.1 million explains why the P/E has flipped from not meaningful to a positive number, but it also means the denominator is still based on a relatively modest profit base.</li> <li>That tension between a premium multiple and a recent return to profitability is exactly what cautious investors focus on when they question how much of the expected 13.1% earnings growth and higher margins should already be priced in.</li> </ul> </li> </ul><p> If you are weighing those valuation concerns, it can help to see how skeptics frame the trade off between a 33.8x P/E and the recent profit swing in their full bear case. <strong>🐻 LivaNova Bear Case</strong></p><h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for LivaNova on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>With both risks and rewards in play, do you feel the balance of this story matches your own view, or challenges it enough to look again? If you want to pressure test that view against the underlying data, take a closer look at the 4 key rewards and 1 important warning sign</p> <h2>See What Else Is Out There</h2> <p>A premium 33.8x P/E alongside modest recent profits and reliance on forecast earnings leaves little room for disappointment if expectations do not play out.</p> <p>If that trade off feels tight, it makes sense to compare LivaNova with stocks that look cheaper on quality metrics by checking out the 44 high quality undervalued stocks</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

LIVN

<p>LivaNova (LIVN) reported Q1 2026 revenue of $362.3 million and basic EPS of $0.41, marking a return to profitability after a loss of $6.01 per share in Q1 2025. The company achieved a trailing twelve-month revenue of $1.4 billion and a net income turnaround from a loss of $242.5 million to a profit of $107.1 million. Despite bullish narratives around new therapies and revenue growth, concerns remain about the high P/E ratio of 33.8x compared to industry averages, raising questions about valuation risks and the sustainability of recent earnings improvements.</p>

LivaNova (LIVN) Profit Return And 33.8x P E Test Bullish Narratives